Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Products Manufactured by BVL of the US Recalled in Response to EMA Recommendation
November 30, 2011
- US FDA Accepts NDA for Potential MS Treatment Carfilzomib: Ono
November 30, 2011
- Shionogi to Implement Organizational Change to Boost Domestic Sales Strength
November 29, 2011
- Pfizer Japan Obtains Approval for Additional Indication for Deep Mycosis Drug Diflucan
November 29, 2011
- AZ to Bolster Its Top Position in Breast Cancer Area
November 29, 2011
- Paraplatin Approved for Breast Cancer: BMKK
November 29, 2011
- Chugai Pharmaceutical to Introduce iPad2 to All MRs and MAs from Mid-January
November 29, 2011
- Mitsubishi Tanabe, Alfresa Obtain Approval for Additional Indication for Sleep Disorder Treatment Modiodal
November 29, 2011
- Pfizer Japan Launches 20 Generics with 10 APIs
November 29, 2011
- Kyowa Pharmaceutical Industry to Launch 2 Generic Drugs Made in India in 2012
November 28, 2011
- Nexium Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
November 28, 2011
- Novartis Files NDA for NVA237 for COPD in Japan
November 28, 2011
- M3 Survey Shows Doctors Want KOL Who Are “Easy to Understand” and Have “Extensive Experience”
November 28, 2011
- Iressa Approved for EGFR Mutation-Positive NSCLC: AZ
November 28, 2011
- Yakult Receives Approval for Changes to Dosage, Administration for Elplat as Post-Operative Therapy for Colorectal Cancer
November 28, 2011
- Chugai Pharmaceutical Obtains Approval for Additional Indication for Anticancer Agent Herceptin
November 28, 2011
- Additional Indication of Solar Keratosis Approved for Mochida Pharmaceutical's Beselna Cream
November 28, 2011
- 26 Major JPMA Member Companies Report Declines in Sales, Profits, with 8.8% Drop in Overseas Sales
November 25, 2011
- Takeda Files NDA for Fixed-Dose Combination of DPP-4 Alogliptin, Metformin with US FDA
November 25, 2011
- MTPC: Telavic Tablets 250 mg to Treat Chronic Hepatitis C
November 25, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…